Effect of supplementary feeding on the side effects associated with cancer therapy with taxanes

Effect of supplementary feeding on the side effects associated with cancer therapy with taxanes - taxanEVENTS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005950

Enrollment

750

Registered

2014-03-06

Start date

2014-03-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50 C34 C61 C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C30 C31 C32 C33 C56

Interventions

Group 1: In this single-arm medicament study the role of nutrition should be studied in the side effects of taxanes with a particular in a relatively large group of patients. Ribodocel = Docetaxel, R

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients: -Consent eligible adult -The decision for the prescribed therapy falls the physican individually before the inclusion of nis taxanes -Prescribing information physican used This Nis is offered oncologically active, practicing physicians

Exclusion criteria

Exclusion criteria: People less than 18 years

Design outcomes

Primary

Measure	Time frame
The influence of the nutritional status of patients on the severity of the side effects of treatment with taxanes (Ribodocel® or Ribotax®)	—

Secondary

Measure	Time frame
Influence of other dietary supplements on the side effects of treatment with taxanes (Ribodocel® or Ribotax®)	—

Countries

Germany

Contacts

Public ContactHayssam Zakaria

NewConceptOncology GmbH

info@n-c-o.de0511 76355123

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026